



# cAMP Receptor Protein (CRP) Binding Interactions with *WhiB1* from *Mycobacterium tuberculosis*

Miray Samuel

Advisor: Dr. Rodrigo Maillard  
Georgetown University Department of Chemistry

## BACKGROUND

*Mycobacterium tuberculosis* is one of the most dangerous human pathogens, claiming ~2 million lives per year. It exhibits extreme antibiotic resistance, which creates a need to better understand the survival mechanisms of *M. tuberculosis* *in vivo*.

The cAMP receptor protein from *M. tuberculosis* (CRP<sub>MTB</sub>) is an essential transcription factor that regulates several important genes for host infection and antibiotic resistance in *M. tuberculosis*.

Previous studies have shown a role for the signaling molecule cAMP in enhancing of the highly characterized CRP<sub>E.coli</sub> binding to specific DNA sequences, which has also been confirmed in CRP<sub>MTB</sub>.

This study analyzes CRP<sub>MTB</sub> binding interactions with the *whiB1* gene, which encodes Wb1 proteins that control developmental processes for the pathogen, with and without cAMP through fluorescence anisotropy. The promoter contains two adjacent binding sites which CRP<sub>MTB</sub> is predicted to bind to with varying affinities.




Figure 1. Crystal structures of apo and cAMP-bound CRP<sub>E.coli</sub> and CRP<sub>MTB</sub>. Dimerization helix is boxed in red.

## MATERIALS AND METHODS





Figure 2. Schematic of the workings of fluorescence anisotropy with generic *WhiB1* construct and CRP.

## RESULTS




Figure 3. (A) Chromatogram of CRP<sub>MTB</sub> protein purification. (B) SDS-PAGE gel utilized to confirm the presence of CRP<sub>MTB</sub> wildtype following the size exclusion chromatography at the end of the protein purification process. (C) Schematic description of the four *whiB1* constructs (i) *WhiB1 CRP1* (26bp) (ii) *WhiB1 CRP2* (26bp), (iii) *WhiB1 Full CRP1* (48bp), and (iv) *WhiB1 Full CRP2*.





Figure 4. Average anisotropy values for four trials of nonstoichiometric titrations of CRP<sub>MTB</sub> with and without cAMP for each *whiB1* construct (5nM). Four trials were performed utilizing 0mM cAMP (circles) and four utilizing 1mM cAMP (triangles) for each *whiB1* promoter. (A) Average anisotropy values for the *WhiB1 CRP1* (short) 26 bp promoter. (B) Average anisotropy values for the *WhiB1 CRP2* (short) 26 bp promoter. (C) Average anisotropy values for the *WhiB1 Full CRP1* 48 bp promoter. (D) Average anisotropy values for the *WhiB1 Full CRP2* 48 bp promoter.



Construct	Promoter length	$k_{DNA}$ (cAMP-bound)	$k_{DNA}$
<i>WhiB1 CRP1</i>	26-bp <i>WhiB1</i> promoter	7.834	$10^{-7} M^{-1}$
<i>WhiB1 CRP2</i>	26-bp <i>WhiB1</i> promoter	7.721	$10^{-7} M^{-1}$
<i>WhiB1 Full CRP1</i>	48-bp <i>WhiB1</i> promoter	8.547	$10^{-7} M^{-1}$
<i>WhiB1 Full CRP2</i>	48-bp <i>WhiB1</i> promoter	8.116	$10^{-7} M^{-1}$

Figure 5. Quantification of the functional behavior of CRP<sub>MTB</sub> when binding with each *whiB1* promoter in the presence of cAMP. Average anisotropy values of CRP<sub>MTB</sub>-*whiB1* binding with 1mM cAMP are represented by blue circles, while solid red lines represent the mathematical fit created using Equation 1. DNA-binding affinities also included ( $k_{DNA}$ ). (A) Fitted data for the *WhiB1 CRP1* promoter. (B) Fitted data for the *WhiB1 CRP2* promoter. (C) Fitted data for the *WhiB1 Full CRP1* promoter. (D) Fitted data for the *WhiB1 Full CRP2* promoter. (E) Table of DNA-binding affinity constants of the constructs in the cAMP-bound state.




Figure 6. Preliminary stoichiometric binding assay results for the binding between CRP<sub>MTB</sub> and the *WhiB1 Full CRP1* promoter with and without cAMP. Stoichiometric titration was performed utilizing 200 nM of the *WhiB1 Full CRP1* promoter and up to 800  $\mu M$  of CRP<sub>MTB</sub> for two trials with 0mM cAMP (blue squares) and two trials with 1mM cAMP (orange triangles). The anisotropy values from the trials were then averaged and normalized to the first point.

## CONCLUSIONS

CRP<sub>MTB</sub> binds with **higher affinity** to the **upstream *WhiB1* CRP1** binding site, but the sites are not exhibiting negative cooperativity on one another, as binding still occurs at the downstream *WhiB1* CRP2 site. This study also confirms the previously studied role of cAMP on CRP<sub>MTB</sub> binding interactions, in that in the presence of cAMP, **high-ordered CRP-DNA oligomers are prevented**.

## ACKNOWLEDGMENTS

Special thanks to Sanuja Mohanaraj, Stephen Dokas, and the rest of the Maillard Lab.

## REFERENCES

- Gárate, F., Dokas, S., Lanfranco, M. F., Canavan, C., Wang, L., Correia, J. J., & Maillard, R. A. cAMP is an allosteric modulator of DNA-binding specificity in the cAMP receptor protein from *Mycobacterium tuberculosis*. *The Journal of biological chemistry*. 2021, 296, 100480. <https://doi.org/10.1016/j.jbc.2021.100480>
- Stapleton, M., Haq, I., Hunt, D. M., Arvig, K. B., Artymiuik, P. J., Buxton, R. S., & Green, J. *Mycobacterium tuberculosis* cAMP receptor protein (Rv3676) differs from the Escherichia coli paradigm in its cAMP binding and DNA binding properties and transcription activation properties. *The Journal of biological chemistry*. 2010, 285(10), 7016–7027. <https://doi.org/10.1074/jbc.M109.047720>
- Davne, T., & McShane, H. Why don't we have an effective tuberculosis vaccine yet?. *Expert review of vaccines*. 2016, 15(8), 1009–1013. <https://doi.org/10.1586/14760584.2016.1170599>
- Singh R, Dwivedi SP, Gaharwar US, Meena R, Rajamani P, Prasad T. Recent updates on drug resistance in *Mycobacterium tuberculosis*. *J Appl Microbiol*. 2020;128(6):1547-1567. doi: 10.1111/jam.14478. Epub 2019 Oct 29. PMID: 31595643.
- Agarwal, N., Lamichhane, G., Gupta, R. et al. Cyclic AMP intoxication of macrophages by a *Mycobacterium tuberculosis* adenylate cyclase. *Nature*. 2009, 460, 98–102. <https://doi.org/10.1038/nature08123>
- Bai, G.; McCue, L. A.; McDonough, K. A. Characterization of *Mycobacterium Tuberculosis* Rv3676 (CRP Mt), a Cyclic AMP Receptor Protein-Like DNA Binding Protein. *J. Bacteriol.* 2005, 187(22), 7795–7804. <https://doi.org/10.1128/JB.187.22.7795-7804.2005>.
- Agarwal, N., Raghunand, T.R., Bishai, W.R. Regulation of the expression of *whiB1* in *Mycobacterium tuberculosis*: role of cAMP receptor protein. *Microbiology*. 2006, 152, 2749–2756. <https://doi.org/10.1099/mic.0.28924-0>.
- Heyduk, T.; Lee, J. C. Escherichia Coli cAMP Receptor Protein: Evidence for Three Protein Conformational States with Different Promoter Binding Affinities. *Biochemistry* 1989, 28 (17), 6914–6924. <https://doi.org/10.1021/bi00443a021>.
- Lanfranco, M. F.; Garate, F.; Engdahl, A. J.; Maillard, R. A. Asymmetric Configurations in a Reengineered Homodimer Reveal Multiple Subunit Communication Pathways in Protein Allostery. *J. Biol. Chem.* 2017, 292 (15), 6086–6093.